StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX)

StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX) in a research report report published on Tuesday morning. The brokerage issued a sell rating on the stock.

Separately, Benchmark restated a hold rating on shares of VolitionRx in a research report on Friday, August 16th.

VolitionRx Stock Up 3.4 %

NYSE VNRX opened at $0.64 on Tuesday. VolitionRx has a 52 week low of $0.43 and a 52 week high of $1.23. The firm has a market capitalization of $58.48 million, a price-to-earnings ratio of -1.42 and a beta of 1.12. The company has a fifty day moving average of $0.65 and a two-hundred day moving average of $0.72.

VolitionRx (NYSE:VNRX) last released its earnings results on Wednesday, August 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.01. The firm had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.34 million. Equities research analysts anticipate that VolitionRx will post -0.31 EPS for the current year.

Insider Activity

In related news, Director Guy Archibald Innes bought 150,000 shares of the company’s stock in a transaction on Tuesday, August 20th. The shares were acquired at an average cost of $0.67 per share, for a total transaction of $100,500.00. Following the purchase, the director now directly owns 406,683 shares of the company’s stock, valued at $272,477.61. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 12.80% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.